Pune: Hikal Unveils Advanced High Potency API Laboratory At Integrated Innovation Centre 

Pune: Hikal Unveils Advanced High Potency API Laboratory At Integrated Innovation Centre

Pune: Hikal Unveils Advanced High Potency API Laboratory At Integrated Innovation Centre

Share This News

Pune, 14 October 2025: Hikal Ltd., the preferred long-term partner for leading global life sciences companies, today announced the inauguration of its state-of-the-art High Potency Active Pharmaceutical Ingredient (HPAPI) Laboratory at its Integrated Innovation Centre in Pune.

This world-class facility marks a significant milestone in Hikal’s innovation journey, further strengthening its end-to-end CDMO capabilities and enhancing its ability to safely develop and test and deliver highly potent compounds for the global pharmaceutical industry.

The new cGMP-compliant HPAPI Laboratory is equipped with state-of-the-art isolators designed to meet Occupational Exposure Band 5 (OEB-5) requirements. The lab is purpose-built to support the development of complex oncology and specialty molecules, including components of Antibody Drug Conjugates (ADCs), Peptide Drug Conjugates (PDCs), and Proteolysis Targeting Chimeras (PROTACs).

IMG-20250927-WA0000

“Our new HPAPI laboratory represents a critical step forward in expanding our capabilities and reinforcing our unwavering commitment to innovation, safety and customer excellence,” said Sameer Hiremath, Vice Chairman & Managing Director, Hikal Ltd. “With this new addition to our technology toolbox, we are well positioned to meet the growing demand for potent molecule development while maintaining the highest global standards of containment and compliance.”

IMG-20250324-WA0012

Key Features of the Facility

  • Segregated entry and exit for personnel and materials to ensure safe operations
  • Complete sequence control from raw material dispensing to final packing within isolators
  • Built-in milling operations to meet precise particle size requirements during development
  • Advanced analytical capabilities including HPLC and GC for in-lab analysis of HPAPIs, avoiding cross-contamination
  • Stringent containment systems, maintaining exposure control to OEB 5, validated through independent third-party surrogate testing

The HPAPI Lab complements Hikal’s existing validation lab, process safety lab, solid state lab, flow chemistry lab, instrumentation and synthesis laboratories, creating a truly integrated innovation ecosystem at the Pune site. This ecosystem supports the seamless transition of projects, from early-phase studies to commercial manufacturing, covering scales from milligrams to >100 Kg batch size in our pilot plant.

With decades of experience in scaling molecules from clinical to commercial, Hikal continues to be a trusted partner for the pharmaceutical, animal health, and specialty chemicals industries, enabling the development and manufacture of APIs and AIs through innovation, flexibility, and best in class ESG.

IMG-20250820-WA0009
85856